Tiffany joined NEA in 2020 and is an investor on the life sciences team where she focuses on medtech, devices, and healthtech investments. She currently observes on the boards of Willow, Allay Therapeutics, Revelle, Setpoint Medical, DOTS, and Intrinsic. She previously observed on the boards of Eargo (NAS: EAR) and Intact Vascular (Philips Acq.)
Previously, Tiffany was at Kaiser Permanente Ventures where she focused on investments across medical devices, healthcare enterprise SaaS, and healthcare services. Prior to KPV, she was a Senior Life Sciences Consultant at L.E.K. Consulting in their Los Angeles and London offices where she led more than 30 strategic projects for top medtech, biotech, and life sciences clients spanning M&A, launch and commercialization strategy, portfolio optimization, and product and geographic expansion. At L.E.K., she had particular expertise in the oncology, allergy/immunotherapy, and pulmonary disease areas as well as in precision medicine, diagnostics, and orphan indications.
Tiffany has also collaborated on research leveraging brain organoid and synthetic biology models to interrogate Alzheimer’s Disease at MIT and worked at Amgen via externship within their Innovation and Customer Experience team. She serves on the Board of Mending Kids International, a non-profit providing surgical care to children in under-resourced communities, and is a national organizer of the community organization Frontline Foods.
Tiffany received a BA in Business Economic Theory from the University of California, Los Angeles and an MBA from Harvard Business School.